CL2022003013A1 - Pirimidinas cicloalquiladas como inhibidores de la ferroportina - Google Patents
Pirimidinas cicloalquiladas como inhibidores de la ferroportinaInfo
- Publication number
- CL2022003013A1 CL2022003013A1 CL2022003013A CL2022003013A CL2022003013A1 CL 2022003013 A1 CL2022003013 A1 CL 2022003013A1 CL 2022003013 A CL2022003013 A CL 2022003013A CL 2022003013 A CL2022003013 A CL 2022003013A CL 2022003013 A1 CL2022003013 A1 CL 2022003013A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- cycloalkylated
- pyrimidines
- methods
- ferroportin inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La materia descrita en el presente documento está dirigida a compuestos inhibidores de ferroportina de Fórmula I o I' y sales farmacéuticas de los mismos, métodos para preparar los compuestos, composiciones farmacéuticas que comprenden los compuestos y métodos para administrar los compuestos para la profilaxis y/o el tratamiento de enfermedades causadas por falta de hepcidina o trastornos del metabolismo del hierro, en particular estados de sobrecarga de hierro, como talasemia, anemia de células falciformes y hemocromatosis, y también lesiones renales.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063016891P | 2020-04-28 | 2020-04-28 | |
US202063127774P | 2020-12-18 | 2020-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022003013A1 true CL2022003013A1 (es) | 2023-06-30 |
Family
ID=75954294
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022003013A CL2022003013A1 (es) | 2020-04-28 | 2022-10-28 | Pirimidinas cicloalquiladas como inhibidores de la ferroportina |
Country Status (18)
Country | Link |
---|---|
US (2) | US11746100B2 (es) |
EP (1) | EP4143178A1 (es) |
JP (1) | JP2023524033A (es) |
KR (1) | KR20230007441A (es) |
CN (1) | CN115836063A (es) |
AU (1) | AU2021263818A1 (es) |
BR (1) | BR112022021806A2 (es) |
CA (1) | CA3180661A1 (es) |
CL (1) | CL2022003013A1 (es) |
CO (1) | CO2022015395A2 (es) |
CR (1) | CR20220556A (es) |
DO (1) | DOP2022000236A (es) |
EC (1) | ECSP22084239A (es) |
IL (1) | IL297624A (es) |
MX (1) | MX2022013518A (es) |
PE (1) | PE20230845A1 (es) |
TW (1) | TW202206421A (es) |
WO (1) | WO2021222363A1 (es) |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
DE3922735A1 (de) | 1989-07-11 | 1991-01-24 | Hoechst Ag | Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
JP4808156B2 (ja) | 2003-08-05 | 2011-11-02 | バーテックス ファーマシューティカルズ インコーポレイテッド | 電位依存型イオンチャネルの阻害剤としての縮合ピリミジン化合物 |
EP2373679B1 (en) | 2008-12-05 | 2017-03-08 | The Regents of The University of California | Mini-hepcidin peptides and methods of using thereof |
AR077999A1 (es) | 2009-09-02 | 2011-10-05 | Vifor Int Ag | Antagonistas de pirimidin y triazin-hepcidina |
CN104011066A (zh) | 2011-12-09 | 2014-08-27 | 加利福尼亚大学董事会 | 经修饰的微型铁调素肽及其使用方法 |
ES2901704T3 (es) | 2013-03-15 | 2022-03-23 | Protagonist Therapeutics Inc | Análogos de hepcidina y usos de los mismos |
EP3046570B1 (en) | 2013-09-20 | 2020-04-22 | University of Virginia Patent Foundation | Compositions and methods for protecting the kidney from ischemia reperfusion injury |
EP3129040A4 (en) | 2014-04-07 | 2018-03-21 | La Jolla Pharmaceutical Company | Hepdicin mimetic peptides and uses thereof |
SG11201610799WA (en) | 2014-06-27 | 2017-01-27 | Protagonist Therapeutics Inc | Hepcidin and mini-hepcidin analogues and uses therof |
WO2016109363A1 (en) | 2014-12-29 | 2016-07-07 | The Regents Of The University Of California | S-Alkylated Hepcidin Peptides and Methods of Making and Using Thereof |
JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
TWI815887B (zh) | 2018-05-15 | 2023-09-21 | 美商愛彼特生物製藥股份有限公司 | 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法 |
US11286243B2 (en) | 2018-12-13 | 2022-03-29 | Global Blood Therapeutics, Inc. | Ferroportin inhibitors and methods of use |
-
2021
- 2021-04-28 CN CN202180047289.0A patent/CN115836063A/zh active Pending
- 2021-04-28 IL IL297624A patent/IL297624A/en unknown
- 2021-04-28 CR CR20220556A patent/CR20220556A/es unknown
- 2021-04-28 BR BR112022021806A patent/BR112022021806A2/pt unknown
- 2021-04-28 EP EP21726289.8A patent/EP4143178A1/en active Pending
- 2021-04-28 CA CA3180661A patent/CA3180661A1/en active Pending
- 2021-04-28 PE PE2022002516A patent/PE20230845A1/es unknown
- 2021-04-28 KR KR1020227041423A patent/KR20230007441A/ko active Search and Examination
- 2021-04-28 US US17/242,731 patent/US11746100B2/en active Active
- 2021-04-28 WO PCT/US2021/029574 patent/WO2021222363A1/en active Application Filing
- 2021-04-28 AU AU2021263818A patent/AU2021263818A1/en active Pending
- 2021-04-28 MX MX2022013518A patent/MX2022013518A/es unknown
- 2021-04-28 TW TW110115440A patent/TW202206421A/zh unknown
- 2021-04-28 JP JP2022566040A patent/JP2023524033A/ja active Pending
-
2022
- 2022-10-28 CO CONC2022/0015395A patent/CO2022015395A2/es unknown
- 2022-10-28 CL CL2022003013A patent/CL2022003013A1/es unknown
- 2022-10-28 DO DO2022000236A patent/DOP2022000236A/es unknown
- 2022-10-28 EC ECSENADI202284239A patent/ECSP22084239A/es unknown
-
2023
- 2023-06-15 US US18/335,480 patent/US20240140932A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2021222363A1 (en) | 2021-11-04 |
ECSP22084239A (es) | 2023-01-31 |
IL297624A (en) | 2022-12-01 |
US11746100B2 (en) | 2023-09-05 |
CA3180661A1 (en) | 2021-11-04 |
CR20220556A (es) | 2022-12-15 |
CN115836063A (zh) | 2023-03-21 |
MX2022013518A (es) | 2023-02-01 |
AU2021263818A1 (en) | 2022-11-03 |
US20240140932A1 (en) | 2024-05-02 |
PE20230845A1 (es) | 2023-05-23 |
BR112022021806A2 (pt) | 2022-12-13 |
CO2022015395A2 (es) | 2022-11-08 |
US20220396562A1 (en) | 2022-12-15 |
KR20230007441A (ko) | 2023-01-12 |
JP2023524033A (ja) | 2023-06-08 |
EP4143178A1 (en) | 2023-03-08 |
TW202206421A (zh) | 2022-02-16 |
DOP2022000236A (es) | 2023-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2019000281A1 (en) | Ferroportin-inhibitor salts | |
CL2020002146A1 (es) | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores hpki para tratar el cáncer. | |
BR112023020483A2 (pt) | Compostos para inibir nlrp3 e usos dos mesmos | |
CO2023008167A2 (es) | Inhibidores de prmt5 | |
MA38398A1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
ECSP088913A (es) | Derivados de pirimidina tieno [3,2-d] utiles como inhibidores de fi3q | |
UY31046A1 (es) | Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones | |
WO2017068089A3 (en) | Ferroportin inhibitors | |
BR112015028501B8 (pt) | Compostos derivados de bipirazol, seus sais, composição compreendendo o composto ou o sal, método de inibição in vitro de uma atividade de jak1, e processo de preparação de sal de ácido fosfórico | |
ECSP10010685A (es) | Sales de 2-fluoro-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparación de las mismas | |
MA35061B1 (fr) | Dérivés de pyrazolospirocétone pour une utilisation comme inhibiteurs d'acétyl-coa carboxylase | |
CO6220902A2 (es) | Formulacion en polvo del valganciclovir | |
UY39032A (es) | Compuestos heterocíclicos como agentes antivirales | |
EA201991916A1 (ru) | 1,4,6-ТРИЗАМЕЩЕННЫЕ-2-АЛКИЛ-1H-БЕНЗО[d]ИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ДИГИДРООРОТАТНЫХ ОКСИГЕНАЗНЫХ ИНГИБИТОРОВ | |
MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
CO6491033A2 (es) | 5-3,4-dicloro-fenil- n-(2-hidroxi-cicloheexil)- 6-(2,2,2-trifluoro etoxi)- nicotinamida y sales de la misma, como agentes que elevan el colesterol hdl | |
CL2022001357A1 (es) | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso | |
CL2022003013A1 (es) | Pirimidinas cicloalquiladas como inhibidores de la ferroportina | |
UY30284A1 (es) | Compuestos de ariloxietilamina apropiados para tratar trastornos que responden a la modulacion del receptor de dopamina d3 | |
AR084197A1 (es) | Composicion para uso topico para el tratamiento de trastornos de la piel | |
CO6612211A2 (es) | Derivado de amida que tiene una acción hipoglucémica y/o una acción protectora de células b o pancreas | |
EA201791321A1 (ru) | Составы ингибитора lfa-1 | |
BR112015019307A8 (pt) | derivados de ácido butanóico substituído com bisfenila, seus usos, e composição farmacêutica | |
AR126052A1 (es) | Derivados de 3-(5-oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona y sus usos | |
BR112022021735A2 (pt) | Compostos úteis para inibir cinase ret |